Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis.
暂无分享,去创建一个
[1] J. Maher. Interactions between Hepatic Stellate Cells and the Immune System , 2001, Seminars in liver disease.
[2] R. DePinho,et al. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. , 2000, Science.
[3] D. Rockey,et al. Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. , 1996, The Journal of clinical investigation.
[4] J. Iredale,et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. , 1998, The Journal of clinical investigation.
[5] Anping Chen,et al. E-box-binding Repressor Is Down-regulated in Hepatic Stellate Cells during Up-regulation of Mannose 6-Phosphate/Insulin-like Growth Factor-II Receptor Expression in Early Hepatic Fibrogenesis* , 1998, The Journal of Biological Chemistry.
[6] D. Sohn,et al. Antifibrotic effects of a polysaccharide extracted from Ganoderma lucidum, glycyrrhizin, and pentoxifylline in rats with cirrhosis induced by biliary obstruction. , 1997, Biological & pharmaceutical bulletin.
[7] M. Zern,et al. Hepatic stellate cells: a target for the treatment of liver fibrosis , 2000, Journal of Gastroenterology.
[8] A. Rolland. From genes to gene medicines: recent advances in nonviral gene delivery. , 1998, Critical reviews in therapeutic drug carrier systems.
[9] A. Burt,et al. Macrophage and hepatic stellate cell responses during experimental hepatocarcinogenesis , 1998, Journal of gastroenterology and hepatology.
[10] O. Chazouilleres,et al. Primary biliary cirrhosis–autoimmune hepatitis overlap syndrome: Clinical features and response to therapy , 1998, Hepatology.
[11] T. Willson,et al. Peroxisome Proliferator-activated Receptors and Hepatic Stellate Cell Activation* , 2000, The Journal of Biological Chemistry.
[12] M. Arthur,et al. Extracellular Matrix Degradation and the Role of Hepatic Stellate Cells , 2001, Seminars in liver disease.
[13] E. De Clercq,et al. Charge modification of plasma and milk proteins results in antiviral active compounds , 1999, Journal of peptide science : an official publication of the European Peptide Society.
[14] V. Carloni,et al. Signal transduction in hepatic stellate cells. , 2008, Liver.
[15] M. Kaplan. The Use of Methotrexate, Colchicine, and Other Immunomodulatory Drugs in the Treatment of Primary Biliary Cirrhosis , 1997, Seminars in liver disease.
[16] D. Rockey,et al. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. , 2000, The Journal of clinical investigation.
[17] J. Iredale,et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. , 2001, Gastroenterology.
[18] W. Meyers,et al. V-PYRRO/NO: AN HEPATO-SELECTIVE NITRIC OXIDE DONOR IMPROVES PORCINE LIVER HEMODYNAMICS AND FUNCTION AFTER ISCHEMIA REPERFUSION1 , 2001, Transplantation.
[19] V. Sandig,et al. Liver-directed gene transfer and application to therapy , 1996, Journal of Molecular Medicine.
[20] W. Border,et al. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. , 1998, Kidney international.
[21] Wu,et al. Pre-clinical trials using hepatic gene delivery. , 1998, Advanced drug delivery reviews.
[22] K. Okita,et al. Prolyl 4-hydroxylase inhibitor (HOE 077) prevents TIMP-1 gene expression in rat liver fibrosis , 1999, Journal of Gastroenterology.
[23] M. Zern,et al. Targeting of therapeutics to the liver: liposomes and viral vectors. , 1999, Alcoholism, clinical and experimental research.
[24] W. Brown,et al. Abnormal surface distribution of the human asialoglycoprotein receptor in cirrhosis , 1992, Hepatology.
[25] G. Nemerow. Cell receptors involved in adenovirus entry. , 2000, Virology.
[26] D. Meijer,et al. Hepatic and intrahepatic targeting of an anti-inflammatory agent with human serum albumin and neoglycoproteins as carrier molecules. , 1993, Biochemical pharmacology.
[27] R. Kok,et al. Development of Proteinaceous Drug Targeting Constructs Using Chemical and Recombinant DNA Approaches , 2001 .
[28] A. Desmoulière,et al. Effect of pentoxifylline on early proliferation and phenotypic modulation of fibrogenic cells in two rat models of liver fibrosis and on cultured hepatic stellate cells. , 1999, Journal of hepatology.
[29] T. C. Peterson. Pentoxifylline prevents fibrosis in an animal model and inhibits platelet‐derived growth factor–driven proliferation of fibroblasts , 1993, Hepatology.
[30] R. Bataller,et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. , 2000, Gastroenterology.
[31] M. Pinzani,et al. Biology of Hepatic Stellate Cells and Their Possible Relevance in the Pathogenesis of Portal Hypertension in Cirrhosis , 1999, Seminars in liver disease.
[32] P. Calès. Apoptosis and liver fibrosis: antifibrotic strategies. , 1998, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[33] A. Ooshima,et al. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[34] A. Gressner,et al. Comparative evaluation of gene delivery devices in primary cultures of rat hepatic stellate cells and rat myofibroblasts , 2000, BMC Cell Biology.
[35] M. Newman,et al. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes. , 1999, The Journal of pharmacology and experimental therapeutics.
[36] E. Ruoslahti,et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease , 1992, Nature.
[37] P. Olinga,et al. Dexamethasone coupled to albumin is selectively taken up by rat nonparenchymal liver cells and attenuates LPS-induced activation of hepatic cells. , 2000, Journal of hepatology.
[38] R. Caporale,et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. , 2000, Gastroenterology.
[39] E. Hanisch,et al. Endothelin-Induced Contraction of the Portal Vein in Cirrhosis , 1999, European Surgical Research.
[40] D. Rockey,et al. Hepatic Blood Flow Regulation by Stellate Cells in Normal and Injured Liver , 2001, Seminars in liver disease.
[41] D. Schuppan,et al. Matrix as a modulator of hepatic fibrogenesis. , 2001, Seminars in liver disease.
[42] V. Carloni,et al. Effect of pentoxifylline on the degradation of procollagen type I produced by human hepatic stellate cells in response to transforming growth factor‐β1 , 1997, British journal of pharmacology.
[43] D. Crabb,et al. The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease. , 2000, Liver.
[44] D. Curiel,et al. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector , 1999, Gene Therapy.
[45] A. Gressner. The cell biology of liver fibrogenesis – an imbalance of proliferation, growth arrest and apoptosis of myofibroblasts , 1998, Cell and Tissue Research.
[46] A. de Gottardi,et al. Overexpression of endothelin-1 in bile duct ligated rats: correlation with activation of hepatic stellate cells and portal pressure. , 2001, Journal of hepatology.
[47] A. Mallat,et al. Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast‐like cells , 1997, Hepatology.
[48] J. Armendáriz-Borunda,et al. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[49] V. Koteliansky,et al. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[50] D. Schuppan,et al. Fibrosis of liver, pancreas and intestine: common mechanisms and clear targets? , 2000, Acta gastro-enterologica Belgica.
[51] C. Gandhi,et al. Enhanced synthesis and reduced metabolism of endothelin-1 (ET-1) by hepatocytes--an important mechanism of increased endogenous levels of ET-1 in liver cirrhosis. , 2000, Journal of hepatology.
[52] D. Roulot,et al. Transforming growth factor β and the liver , 2001 .
[53] G. Batist,et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] P. Olinga,et al. Albumin modified with mannose 6‐phosphate: A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells , 1999, Hepatology.
[55] Y. Kamegaya,et al. Enhanced expression of endothelin receptor subtypes in cirrhotic rat liver. , 2001, Liver.
[56] E. Wisse,et al. Insulinlike growth factor—ii/mannose 6‐phosphate receptor is expressed on ccl4‐exposed rat fat‐storing cells and facilitates activation of latent transforming growth factor‐β in cocultures with sinusoidal endothelial cells , 1995 .
[57] A. Gerbes,et al. The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. , 1998, Journal of hepatology.
[58] G. Wu,et al. Hepatocyte-directed Gene Delivery by Receptor-mediated Endocytosis , 1999, Seminars in liver disease.
[59] L. Ferrell,et al. Low proliferative activity in macroregenerative nodules: evidence for an alternate hypothesis concerning human hepatocarcinogenesis. , 2008, Liver.
[60] A. Gressner,et al. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. , 1997, General pharmacology.
[61] H. Yoshiji,et al. Angiotensin‐II type 1 receptor interaction is a major regulator for liver fibrosis development in rats , 2001, Hepatology.
[62] S. Friedman. Cytokines and Fibrogenesis , 1999, Seminars in liver disease.
[63] D. Zeeuw,et al. (Glyco)-protein drug carriers with an intrinsic therapeutic activity : The concept of dual targeting , 1996 .
[64] M. Rugge,et al. Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy. , 1996, Journal of hepatology.
[65] J. Henriksen,et al. Splanchnic and systemic hemodynamic derangement in decompensated cirrhosis. , 2001, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[66] S. Thung,et al. Hepatic stellate cell activation in dysplastic nodules: evidence for an alternate hypothesis concerning human hepatocarcinogenesis. , 2008, Liver.
[67] P. Waring,et al. Gliotoxin and related epipolythiodioxopiperazines. , 1996, General pharmacology.
[68] P. Olinga,et al. Characteristics of the hepatic stellate cell-selective carrier mannose 6-phosphate modified albumin (M6P(28)-HSA). , 2001, Liver.
[69] G. Feldmann,et al. Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation. , 1997, Journal of hepatology.
[70] D. de Zeeuw,et al. Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme. , 1999, The Journal of pharmacology and experimental therapeutics.
[71] D. Meijer,et al. Drug targeting to the kidney with low-molecular-weight proteins , 1994 .
[72] D. Schuppan,et al. Successful Targeting to Rat Hepatic Stellate Cells Using Albumin Modified with Cyclic Peptides That Recognize the Collagen Type VI Receptor* , 2000, The Journal of Biological Chemistry.
[73] F. Marra,et al. Cytokine Receptors and Signaling in Hepatic Stellate Cells , 2001, Seminars in liver disease.
[74] G. Molema,et al. Targeting of sugar- and charge-modified albumins to fibrotic rat livers: the accessibility of hepatic cells after chronic bile duct ligation. , 1998, Journal of hepatology.
[75] W. Klepetko,et al. Decreased hepatic function in patients with hepatoma or liver metastasis monitored by a hepatocyte specific galactosylated radioligand. , 1990, British Journal of Cancer.
[76] A. Gentilini,et al. Inhibition by pentoxifylline of extracellular signal‐regulated kinase activation by platelet‐derived growth factor in hepatic stellate cells , 1996, British journal of pharmacology.
[77] S. Friedman,et al. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver. , 1992, The Journal of clinical investigation.
[78] P. Olinga,et al. Targeting dexamethasone to Kupffer cells: Effects on liver inflammation and fibrosis in rats , 2001, Hepatology.
[79] D. Webb,et al. Altered peripheral vascular responses to exogenous and endogenous endothelin‐1 in patients with well‐compensated cirrhosis , 2001, Hepatology.
[80] S. Friedman,et al. Fibrogenesis I. New insights into hepatic stellate cell activation: the simple becomes complex. , 2000, American journal of physiology. Gastrointestinal and liver physiology.
[81] A. Gressner,et al. LIM-domain protein cysteine- and glycine-rich protein 2 (CRP2) is a novel marker of hepatic stellate cells and binding partner of the protein inhibitor of activated STAT1. , 2001, The Biochemical journal.
[82] C. O’Riordan,et al. Strategies to adapt adenoviral vectors for targeted delivery. , 2003, Methods in molecular medicine.
[83] P. Stewart,et al. Role of alpha(v) integrins in adenovirus cell entry and gene delivery. , 1999, Microbiology and molecular biology reviews : MMBR.
[84] W. Jiménez,et al. Chronic blockade of endothelin receptors in cirrhotic rats: hepatic and hemodynamic effects. , 1999, Gastroenterology.
[85] R. Groszmann,et al. The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough , 2002, Hepatology.
[86] P. Angelberger,et al. Functional liver imaging with 99 Tcm-galactosyl‐neoglycoalbumin (NGA) in alcoholic liver cirrhosis and liver fibrosis , 1991, Nuclear medicine communications.
[87] A. Panduro,et al. Treatment with anti-transforming growth factor beta antibodies influences an altered pattern of cytokines gene expression in injured rat liver. , 1998, Biochimica et biophysica acta.
[88] D. Schuppan,et al. Regulation of the Hepatic Endothelin System in Advanced Biliary Fibrosis in Rats , 2000, Clinical chemistry and laboratory medicine.
[89] E. Schacht,et al. The crucial role of spacer groups in macromolecular prodrug design , 1996 .
[90] G. Hofstede,et al. Liposomal doxorubicin‐induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages , 1995, International journal of cancer.
[91] D. Schuppan,et al. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. , 2000, Gastroenterology.
[92] Y Ando,et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. , 2001, Gastroenterology.
[93] M. Ahmad,et al. Induction of stromelysin gene expression by tumor necrosis factor alpha is inhibited by dexamethasone, salicylate, and N-acetylcysteine in synovial fibroblasts. , 1999, The Journal of pharmacology and experimental therapeutics.
[94] F. Sánchez‐Madrid,et al. Cell adhesion molecules: selectins and integrins. , 1999, Critical reviews in immunology.
[95] D. Rockey,et al. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance , 1996, Hepatology.
[96] G. Abrams,et al. Endothelin-1 stimulation of endothelial nitric oxide synthase in the pathogenesis of hepatopulmonary syndrome. , 1999, The American journal of physiology.
[97] G. Molema,et al. Targeting of Drugs to the Liver , 1995, Seminars in liver disease.
[98] G. Zimmerman,et al. Endothelial cell interactions with granulocytes: tethering and signaling molecules. , 1992, Immunology today.
[99] G. Groothuis,et al. Oxford Textbook of Clinical Hepatology , 1999 .
[100] A. Morelli,et al. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[101] R. Farzaneh-Far,et al. Nitric oxide and the liver. , 2001, Liver.